ISLAMABAD, AUGUST 15: Human insulin has been successfully introduced under the brand name “Ferulin” by BF Biosciences Limited, a division of Ferozsons Laboratories Limited (PSX: FEROZ).
“This launch represents a critical turning point in our efforts to STOP DIABETES, diversify our product line, and improve market access to life-saving medications. The business informed the major bourse on Thursday that Ferulin has been created with the highest quality standards and is aimed to give patients throughout Pakistan with an inexpensive and effective diabetic medication.
BF Biosciences Limited, the first biotech plant in Pakistan, has dedicated itself for more than ten years to creating vital medications for the treatment of HCV, cancer, cardiology, and other therapeutic fields. “The growth of our subsidiary will be positively impacted by Ferulin, which will further strengthen our mission to address unmet patient needs,” the document continued.
This occurs a little more than a week after BF Biosciences Limited submitted an application to list on PSX’s Main Board. BF Bioscience, Pakistan’s first CGMP biotech formulation firm, was established in 2006 as a ground-breaking joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina.
